Rani Therapeutics Holdings, Inc. (RANI)
NASDAQ: RANI · Real-Time Price · USD
0.9600
+0.1227 (14.65%)
At close: Apr 15, 2026, 4:00 PM EDT
0.9644
+0.0044 (0.46%)
After-hours: Apr 15, 2026, 6:10 PM EDT
RANI Employees
As of December 31, 2025, Rani Therapeutics Holdings had 71 total employees, including 69 full-time and 2 part-time employees. The number of employees decreased by 35 or -33.02% compared to the previous year.
Employees
71
Change (1Y)
-35
Growth (1Y)
-33.02%
Revenue / Employee
$23,000
Profits / Employee
-$417,930
Market Cap
95.73M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 71 | -35 | -33.02% | 69 | 2 |
| Dec 31, 2024 | 106 | -34 | -24.29% | 105 | 1 |
| Dec 31, 2023 | 140 | -23 | -14.11% | 140 | 0 |
| Dec 31, 2022 | 163 | 49 | 42.98% | 163 | 0 |
| Dec 31, 2021 | 114 | 43 | 60.56% | 114 | 0 |
| Sep 30, 2021 | 91 | 20 | 28.17% | 91 | 0 |
| Jun 30, 2021 | 78 | - | - | 78 | 0 |
| Mar 31, 2021 | 71 | - | - | 71 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Fortress Biotech | 101 |
| Fractyl Health | 100 |
| Pelthos Therapeutics | 92 |
| InflaRx | 65 |
| aTyr Pharma | 60 |
| NeurAxis | 24 |
| Q32 Bio | 24 |
RANI News
- 6 days ago - Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy - GlobeNewsWire
- 20 days ago - Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update - GlobeNewsWire
- 21 days ago - Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization - GlobeNewsWire
- 27 days ago - Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer - GlobeNewsWire
- 3 months ago - Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen - GlobeNewsWire
- 5 months ago - Rani Therapeutics to Participate in the Evercore Healthcare Conference - GlobeNewsWire
- 5 months ago - Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update - GlobeNewsWire